Pneumovax

(redirected from Pneumococcal polysaccharide vaccine)
Also found in: Dictionary, Thesaurus, Acronyms, Wikipedia.
Related to Pneumococcal polysaccharide vaccine: pneumococcal vaccine, Pneumococcal conjugate vaccine

Pneumovax

A vaccine that is given to splenectomy patients to protect them against bacterial infections. Other vaccines include Pnu-Imune and Menomune.
Mentioned in: Splenectomy
Gale Encyclopedia of Medicine. Copyright 2008 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
IRR, incidence rate ratio; PPV23-13, 23- valent pneumococcal polysaccharide vaccine serotype cases, excluding those also contained in the 13-valent pneumococcal conjugate vaccine; NVT, nonvaccine type serotype cases.
Cheesman et al., "Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation," Vaccine, vol.
The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453.
Starting August 5, the seasonal influenza and pneumococcal polysaccharide vaccines will be available at all 32 primary healthcare centres of Seha's Ambulatory Healthcare Services (AHS).
Conversely, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) showed limited effectiveness against serotypes unique to that vaccine in the study, which included 699 cases and more than 10,000 controls, Olivia Almendares, an epidemiologist at the Centers for Disease Control and Prevention, Atlanta, and her colleagues reported at the International Conference on Emerging Infectious Diseases.
This vaccine is available in two types: PCV or PCV 13 pneumococcal conjugate vaccine; and PPSV or PPSV 23 pneumococcal polysaccharide vaccine (CDC, 2016).
This FDA's decision to approve the label expansion is based on the submission and review of data from the company's open-label, Phase 3 trial of Prevnar 13 in adults who were not previously vaccinated with the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
Another noteworthy change is in the amount of time recommended between receiving the 13-valent pneumococcal conjugate vaccine (PCV13) and the subsequent 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults aged 65 years and older who are deemed "immunocompetent."
* Interval change for 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) from "6 to 12 months" to "at least 1 year" for adults aged [greater than or equal to] 65 years who do not have immunocompromising conditions, anatomical or functional asplenia, cerebrospinal fluid leaks, or cochlear implants (1).
In addition, the analysis showed that 59% of disease among adults 18-64 years of age occurred in persons who had an indication for receiving 23-valent pneumococcal polysaccharide vaccine (PPV23).

Full browser ?